Skip to main content
. Author manuscript; available in PMC: 2023 Jul 18.
Published in final edited form as: J Neurosurg. 2022 Sep 16;138(5):1302–1312. doi: 10.3171/2022.7.JNS22585

TABLE 2.

Genes sorted by neuroinflammatory pathways in analysis 1 comparing WHO grade III meningiomas with WHO grade I meningiomas from benign controls

Pathway (annotated by NanoString) Genes Annotated to Pathway (n) DEG w/in Pathway* Genes†
Microglia‡ 187 28 Top 5 downregulated: P2RY12, NPNT, CX3CR1, JAM2, IGF1
Top 5 upregulated: RRM2, SPP1, LMNB1, TPD52, SLC2A1
Cytokine‡ 117 8 Downregulated: CSFR1, TNFRSF25, CX3CR1, KIT, IL1R1
Upregulated: BIRC3, NEFL
Inflammatory signaling 102 3 Downregulated: CD74, FGL2
Upregulated: BIRC3
Innate immune system 144 2 Downregulated: MAPK10
Upregulated: BIRC3
Oligodendrocyte 27 5 Downregulated: ENPP6, GSN
Upregulated: MAG, MOBP, MYRF
Adaptive immune response 130 9 Downregulated: KIT, BLNK, CD74, MAPK10, CTSF, SIGLEC8
Upregulated: NEFL, KIF2C, TUBB4A
Astrocyte 55 7 Downregulated: C4A, ENTPD2
Upregulated: SLC6A1, SERPIN3A, CP, SOX9, PTX3
Neuron 81 5 Downregulated: None
Upregulated: TUBB4A, PPFIA4, SLC6A1, TPD52, NEFL
*

For all analyses, q < 0.09 and > 2-fold change in gene expression.

†

Up-/downregulation in grade III meningiomas compared with grade I meningiomas from benign controls.

‡

Heatmaps of the microglia- and cytokine-associated DEGs in analysis 1 can be seen in Supplementary Material S3.